PDCD1 and non-small cell lung carcinoma: PD-1/PD-L1 immunotherapy with nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), and atezolizumab (anti-PD-L1) are approved by the USA Food and Drug Administration for the treatment of advanced NSCLC [15,16,17,18,19,20].